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Abstract
JAK1 and JAK3 are recurrently mutated in acute lymphoblastic leukemia. These
tyrosine kinases associate with heterodimeric cytokine receptors such as IL-7R or
IL-9R, in which JAK1 is appended to the specific chain and JAK3 to the common
gamma chain. Here, we studied the role of these receptor complexes in mediating
the oncogenic activity of JAK3 mutants. While JAK3(V674A) and the majority of
other JAK3 mutants needed to bind to a functional cytokine receptor complex in
order to constitutively activate STAT5, JAK3(L857P) was unexpectedly found to
not depend on such receptor complexes for its activity, which was induced without
receptor or JAK1 co-expression. Introducing a mutation in the FERM domain
that abolished JAK-receptor interaction did not affect JAK3(L857P) activity,
while it inhibited the other receptor-dependent mutants. The same cytokine
receptor independence as for JAK3(L857P) was observed for homologous L(857)
mutations of JAK1 and JAK2 and for JAK3(L875H). This different...
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Background: JAK3, a tyrosine kinase 
associated to cytokine receptors, is frequently 
mutated in leukemia. 
Results: JAK3L857P induces constitutive signaling 
independently of cytokine receptors and JAK1, in 
contrast to other JAK mutants 
Conclusion: Different JAK mutants signal 
through distinct mechanisms and show different 
sensitivity to JAK1- or JAK3-specific inhibitors 
Significance: Depending on the JAK residue 
mutated, patients will require different treatments 
 
ABSTRACT 
JAK1 and JAK3 are recurrently mutated 
in acute lymphoblastic leukemia. These tyrosine 
kinases associate with heterodimeric cytokine 
receptors such as IL-7R or IL-9R, in which 
JAK1 is appended to the specific chain and 
JAK3 to the common gamma chain. Here, we 
studied the role of these receptor complexes in 
mediating the oncogenic activity of JAK3 
mutants. While JAK3V674A and the majority of 
other JAK3 mutants needed to bind to a 
functional cytokine receptor complex in order to 
constitutively activate STAT5, JAK3L857P was 
unexpectedly found to not depend on such 
receptor complexes for its activity, which was 
induced without receptor or JAK1 co-expression. 
Introducing a mutation in the FERM domain that 
abolished JAK-receptor interaction did not affect 
JAK3L857P activity, while it inhibited the other 
receptor-dependent mutants. The same cytokine 
receptor independence as for JAK3L857P was 
observed for homologous L857 mutations of 
JAK1 and JAK2 and for JAK3L875H. 
This different cytokine receptor 
requirement correlated with different 
functional properties in vivo and with distinct 
sensitivity to JAK inhibitors. Transduction of 
murine hematopoietic cells with JAK3V674A led 
homogenously to lymphoblastic leukemias in 
BALB/c mice. In contrast, transduction with 
JAK3L857P induced various types of lymphoid 
and myeloid leukemias. Moreover, Ruxolitinib, 
which preferentially blocks JAK1 and JAK2, 
abolished the proliferation of cells transformed 
by the receptor-dependent JAK3V674A, yet proved 
much less potent on cells expressing JAK3L857P. 
These particular cells were, in contrast, more 
sensitive to JAK3-specific inhibitors. Altogether, 
our results showed that different JAK3 
mutations induce constitutive activation through 
distinct mechanisms, pointing to specific 
therapeutic perspectives. 
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JAK3 is a member of the Janus kinase 
(JAK) family, which comprises three other 
tyrosine kinases: JAK1, JAK2, and TYK2. 
These intracellular kinases are associated with a 
wide variety of cytokine receptors that lack 
intrinsic kinase activity. While the three other 
JAKs are ubiquitously expressed and can bind 
various receptor chains, JAK3 is exclusively 
associated with the common gamma chain (γc), 
and both genes are preferentially expressed in 
hematopoietic cells. γc partners with a specific 
alpha (or beta) chain that binds JAK1 to form 
the heterodimeric receptor complexes for IL-2, 
IL-4, IL-7, IL-9, IL-15, and IL-21 cytokines, 
key players of lymphoid development. For the 
IL-2 receptor complex (IL-2R), IL-2 
stimulation revealed JAK1 to be responsible 
for the phosphorylation of JAK3 and signal 
transducers and activators of transcription 5 
(STAT5), with the role of JAK3 being to 
phosphorylate JAK1(1).  
The JAKs possess three functional 
domains that are well conserved. The kinase 
domain is the catalytic domain of the tyrosine 
kinases, located at the carboxyl-terminal end 
(C-terminus). Adjacent to this is the 
pseudokinase domain, which presents a 
kinase-like sequence, yet lacks critical 
residues required for proper catalytic activity. 
This domain is supposed to prevent 
inappropriate activation of the kinase domain 
in the absence of cytokine stimulation (2). The 
amino(N)-terminus contains the FERM (band-
4.1, ezrin, radixin, moesin) domain. This 
domain mediates direct JAK interaction with 
the intracellular portion of cytokine receptors 
(3). Mutations disturbing the structural 
integrity of the extreme N-terminus of the 
FERM domain are interfering with γc 
association, as illustrated e.g. by the Y100C 
mutation of JAK3 (4). 
The JAK3Y100C mutation was 
described in patients suffering from severe 
combined immunodeficiency (SCID) (5). This 
germline JAK3 inactivating mutation 
abrogates the γc-dependent cytokine signaling 
essential for lymphoid cell development, 
leading to a profound defect in T, B, and NK 
cells. In contrast to these inactivating 
mutations, acquired JAK3 activating point 
mutations have been described in various 
leukemia types, such as T-cell acute 
lymphoblastic leukemia (T-ALL) (6), acute 
megakaryoblastic leukemia (AMKL) (7) or 
juvenile myelomonocytic leukemia (JMML) 
(8) resulting in constitutive JAK activation 
and STAT phosphorylation. 
The severe effect of JAK3 signaling 
impairment specifically impacting on 
lymphoid development in SCID patients has 
instigated the development of 
immunosuppressive drugs targeting this kinase. 
Tofacitinib, a type-I JAK inhibitor targeting 
JAK3 (1), is currently an approved treatment 
for rheumatoid arthritis in the United States. 
This drug is being assessed for use in the 
treatment of T-cell specific autoimmune 
diseases, such as psoriasis, multiple sclerosis, 
and inflammatory bowel disease, as well as for 
the prevention of organ transplant rejection 
(9,10). While originally described as a 
selective JAK3 inhibitor, tofacitinib also 
inhibits JAK1, and its efficacy is likely due to 
combined inhibition of both kinases (1,11). On 
the other hand, JAK inhibitors are also 
currently being investigated for the treatment 
of hematological malignancies caused by 
abnormal JAK activation. Ruxolitinib, a 
JAK1/2 type-I inhibitor, is currently 
administered in the treatment for 
myeloproliferative neoplasms (MPNs), which 
are frequently associated with the V617F 
activating mutation in JAK2 (12). In line with 
the results observed with JAK inhibitor use in 
MPN treatment, these inhibitors represent an 
appealing therapeutic strategy for leukemia 
cases associated with JAK3 activation. 
This study sought to gain more insight 
into the potential use of JAK inhibitors in 
mutated JAK3-driven malignancies. We 
therefore decided to first determine if ALL-
associated JAK3 mutants need to bind γc in order 
to be constitutively active, then to test the 
sensitivity of different mutants to JAK inhibitors. 
 
EXPERIMENTAL PROCEDURES 
Cells, cell culture and cytokines- Ba/F3 pro-B 
cells were cultured in Iscove-Dulbecco’s 
medium supplemented with 10% fetal bovine 
serum, 50µM ß-mercaptoethanol, 0.55 mM L-
arginine, 0.24 mM L-asparagine, 1.25 mM L-
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glutamine and in the presence of murine IL-3. 
Autonomous Ba/F3 cells expressing JAK3 
mutants or BCR-ABL were cultured without 
IL-3. BCR-ABL transduced Ba/F3 cells were 
a kind gift of Jean-Baptiste Demoulin 
(Université catholique de Louvain, Brussels, 
Belgium). HEK293 human embryonic kidney 
cells and JAK1 deficient U4C cells were 
grown in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine 
serum. These cells do not express endogenous 
IL-9Rα, γc and JAK3.  
Plasmid constructions- Human (h)JAK3 
mutants and double mutants cDNA’s (Y100A, 
M511I, A572V, V674A, V674A/Y100A, 
L857P, L857A, L857E and L857P/Y100A), 
murine (m)JAK1 mutants and double mutants 
(V658F, K907A as kinase-dead mutation, 
L910P and L910P/Y107A), and mJAK2 
mutants and double mutants (V617F, L884P 
and L884P/Y114A) were generated using 
QuickChange XL II site-directed mutagenesis 
kit (Stratagene, La Jolla, California) and 
subcloned into the pMX-IRES-CD4 (JAK3) or 
pMX-IRES-GFP (JAK1 and JAK2) 
biscistronic retroviral vectors upstream of the 
IRES. The WT, V674A, L857Q, L875H, 
P906S and E958K hJAK3 pMSCV-GFP 
plasmids were described earlier (13). 
Mutagenesis was performed on the WT 
plasmid to create Y824A, T848A, L857P and 
L857P/Y100A hJAK3 mutants. WT hJAK3 
and hIL-9 receptor α cDNA were subcloned 
into the pMX-IRES-CD4 biscistronic 
retroviral vector. WT mJAK1, WT mJAK2 
and human common γ chain cDNA were 
subcloned into the pMX-IRES-GFP 
biscistronic retroviral vector.  
Virus production, stable DNA transfections, 
analysis of transfected cells- Retroviral 
supernatants were generated by transient 
transfection of HEK293T cells with the 
packaging plasmid pCL-Eco (coding for 
gag/pol/env) and biscistronic vectors encoding 
the gene of interest and human CD4 as marker, 
and used for infection of 0.5 x 106  Ba/F3 cells. 
HEK293 cells were transfected with 3.75 µg 
of pCL-Eco and 3.75 µg of the different 
constructs with 22.5 µl of TransIT-LT1 
Transfection Reagent (Mirus). The next day, 
supernatants were collected and added to 
Ba/F3 cells for the spin-infection (two hours 
incubation at 1000g at room temperature). 
This last step was repeated the day after to 
increase the transfection level. Expression of 
the markers was analyzed by FACS (BD 
FACSCaliburTM flow cytometer), using a PE-
coupled antibody against hCD4 (#555347, BD 
Pharmingen) diluted 1/30. For murine bone 
marrow cells transduction, mutated JAK3 
pMSCV-GFP viral vectors were produced in 
HEK293T cells using an EcoPack packaging 
plasmid and TurboFect transfection reagent 
(Fermentas). Virus was harvested after 48 
hours. 
Dual luciferase assay- STAT5 transcriptional 
activity was assessed by measurements of 
luciferase expression in HEK293 cells upon 
transient transfection of appropriate cDNA 
constructs and pLHRE-luc vector harboring 
tandem copies of the STAT5-inducible 
lactogenic hormone response element (LHRE) 
of the rat β-casein promoter, inserted upstream 
a luciferase gene (14). Another reporter 
plasmid, Renilla luciferase (pRLTk, Promega), 
was co-transfected as an internal transfection 
control. Transient transfection of HEK293 
cells by LipofectAMINE (Invitrogen) was 
previously described (15). 24 hours after 
transfection, luciferase assays were performed 
using the Dual Luciferase Reporter Assay 
system (Promega). 
Western blots- For Western Blot analysis of 
JAK3 expression in HEK293 cells, 4 x 105 
cells were transfected with 1 µg of different 
JAK3 constructs with LipofectAMINE 
(Invitrogen) as previously described (15). Cell 
lysate preparation, gel electrophoresis and 
transfer to nitrocellulose membranes were 
performed as previously described (16). 
Phosphorylation of signaling proteins was 
investigated with following phospho-specific 
antibodies from Cell Signaling Technology: 
anti-pY1034/1035 JAK1 (#3331), anti-
pY980/981 JAK3 (#5031), anti-pY705 STAT3 
(#9131), anti-pY694 STAT5 (#9351) and anti-
pT202/Y204 ERK1/2 (#9101). Blots were re-
probed with anti-JAK1 (#3332), anti-JAK3 
(#3775), anti-STAT3 (#9132) (Cell Signaling 
Technology, Beverly, MA), anti-STAT5 
(#SC-835, Santa Cruz Biotechnology) or anti-
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β-actin (#A5441, Sigma) antibodies, as a 
control. 
Murine bone marrow transplantation- 
BALB/c mice were purchased from Charles 
River Laboratories. Harvest of bone marrow 
cells from male donor mice, lineage negative 
cells enrichment, transduction with viral 
supernatant and injection into irradiated 
female recipient mice was performed as 
previously described (13). After sacrifice of 
the mice, single-cell suspensions were 
prepared from peripheral blood, bone marrow, 
spleen, thymus and lymph nodes. Cells were 
analyzed on a FACSCanto flow cytometer 
(BD Bio-sciences).  
Proliferation assays- For knockdown 
experiments, 1.5 × 106 IL-3 dependent control 
Ba/F3 cells or growth factor-independent 
Ba/F3 cells obtained after transduction with 
ALL-associated JAK3 mutants (V674A and 
L857P) and double mutant (L857P/Y100A) 
were resuspended in 400 µL of medium 
containing 200 nM siRNA duplexes (Silencer 
Select Il2rg Mouse, Ambion cat#s68269 ; 
Stealth siRNA Jak1 Mouse, Invitrogen 
cat#mss205625 ; Silencer Select Negative 
Control No. 1 siRNA, Ambion cat#4390843 ; 
Stealth RNAi™ siRNA Negative Control, 
Invitrogen cat#12935-400) and then 
transferred to 4-mm cuvettes (Biorad). Cells 
were electroporated (260V, 90Ω, 1500µF) and 
seeded in 96-well plates at 10,000 cells/well. 
For JAK inhibitors treatment, Ba/F3 cells 
stably transduced with ALL-associated JAK3 
mutants (V674A and L857P), double mutant 
(L857P/Y100A) or BCR-ABL were seeded in 
96-well plates at 5,000 cells/well in the 
presence of increasing concentrations of 
Ruxolitinib (INCB018424, Haoyuan 
Chemexpress Co), NIBR3048 (Tocris 
Bioscience (TSC21311), (17)) or Tofacitinib 
(CP-690550, Selleckchem). After 72 hours, 
methyl-H3Thymidine (Amersham, 
cat#TRK120) was added to the cells for 4 
hours, and thymidine incorporation was 
measured with a Top Count microplate 
scintillation counter (Canberra-Packard, 
Meriden, CT).  
JAK3 structure- The three-dimensional 
structural model of the pseudokinase domain 
of JAK3 was obtained by employing the 
SWISS-MODEL server and was 
superimposed on TYK2 JH1-JH2 crystal 
structure (PDB code: 4OLI) as template, 
together with the JAK3 kinase domain crystal 
structure (PDB code: 1YVJ), using the Pymol 
program. 
 
RESULTS 
ALL-associated JAK3 mutants signal through 
a functional cytokine receptor complex, except 
the L857P mutant- More and more patients 
suffering from different types of leukemia, 
such as ALL, AMKL or JMML, have been 
reported to exhibit mutations in the JAK3 gene 
(6-8,18,19). These mutations were often 
characterized as activating (7,18-20), yet little 
is known about their activation mechanism. Of 
the other JAK kinases, JAK2 V617F, found in 
95% of polycythemia vera cases, has been 
shown to be dependent on homodimeric 
receptors, like the erythropoietin receptor 
(EpoR), in order to become active (20). 
Similar results were obtained for the activating 
JAK1 V658F and A634D mutants, which 
needed to bind to IL-9 receptor alpha or IL-2 
receptor beta in order to form homo- or 
heterodimeric cytokine receptor complexes 
able to mediate constitutive signaling (21). 
Furthermore, the active JAK3A572V mutant 
requires heterodimeric complexes formed by 
IL-9 receptor alpha or IL-2 receptor beta and 
γc (22). We sought to determine if ALL-
associated JAK3 mutants shared similar 
receptor-dependent mechanisms of 
constitutive signaling. To this end, we studied 
four activating JAK3 mutants scattered 
throughout the kinase and pseudokinase 
domains, namely M511I, A572V, V674A, and 
L857P identified in patients with T-ALL 
(Marco Tartaglia, unpublished data). We took 
advantage of HEK293 cells that are deficient 
in JAK3 and γc, the only cytokine receptor 
chain known to bind JAK3. WT JAK3 and the 
four mutants were transiently transfected into 
HEK293 cells, in combination with a STAT5-
responsive reporter construct. This 
transfection was carried out both in the 
absence of IL-9Rα or γc, or in their presence 
in order to reconstitute a functional IL-9R 
complex. As shown in figure 1, the four tested 
JAK3 mutants induced constitutive STAT5 
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activation, although for the M511I, A572V, 
and V674A mutants, this was achieved only in 
the presence of a functional IL-9R complex 
(γc and IL-9Rα). Surprisingly, JAK3L857P 
induced STAT5 activation even without co-
expression of any receptor chain. This 
observation suggested a receptor-independent 
activity that was specific to JAK3L857P. An 
alternative hypothesis would be the 
involvement of another cytokine receptor 
chain that could bind JAK3 and would be 
expressed in HEK293. To exclude the latter 
hypothesis, we tested the effect of a SCID 
mutation localized in the FERM domain of 
JAK3 (Y100C) that inactivates the JAK by 
disabling its binding to γc (4,5). In fact, 
mutation of this conserved hydrophobic 
residue in JAK FERM domains disturbs the 
structural integrity of parts of this FERM 
domain which plays an essential role in all 
JAK-cytokine receptor interactions, as also 
shown for the homologous mutations of JAK1 
(Y107A) (3) and JAK2 (Y114A) (23). We 
introduced the Y100A mutation into a WT, 
V674A and L857P JAK3 and evaluated the 
capacity of each mutant and double mutant to 
mediate constitutive signaling. As illustrated 
in figure 2A, the JAK3V674A activity in the 
presence of the IL-9R complex was abrogated 
by introducing the Y100A mutation, thereby 
confirming the essential role of Y100 for 
receptor binding. This observation contrasted 
with the results obtained for JAK3L857P for 
which introducing the Y100A mutation did 
not abrogate its activity. On the contrary, 
increased constitutive signaling in the absence 
of a functional receptor was observed. Notably, 
the expression level of each JAK3 mutant was 
similar under all experimental conditions 
(figure 2B).  
To confirm the lack of γc requirement for 
constitutive JAK3L857P signaling in 
hematopoietic cells, we downregulated the 
expression of endogenous murine γc in growth 
factor-independent Ba/F3 cells obtained after 
stable transduction with JAK3V674A, JAK3L857P, 
and JAK3L857P/Y100A, or in IL-3 dependent 
control Ba/F3 cells. Figure 2C shows that 
siRNA-mediated knockdown of γc resulted in 
a significant decrease of the proliferation of 
Ba/F3 cells transformed with JAK3V674A 
compared to the proliferation observed after 
control siRNA treatment, while no decrease in 
proliferation was observed for cells 
transformed by JAK3L857P or JAK3L857P/Y100A. 
These results confirm the unique capacity of 
JAK3L857P to induce cytokine-receptor 
independent constitutive signaling.  
Cytokine receptor complexes are formed of 
two receptor chains, each associated with one 
JAK. In γc-associated receptor complexes, 
such as IL-7 or IL-9 receptor, JAK3 and JAK1 
are believed to interact and cross-
phosphorylate each other to enable signaling. 
In order to assess the role of JAK1 in mutant 
JAK3-induced signaling, we took advantage 
of JAK1-deficient U4C cells. As shown in 
figure 3A, in the absence of JAK1, the 
JAK3V674A was unable to activate STAT5, 
even when cytokine receptor chains were 
expressed. This activity was restored by co-
expression with JAK1WT, but not with a 
kinase-dead (KD) JAK1. The results obtained 
for JAK3L857P, shown in figure 3B, indicated 
that the activity of this mutant is entirely 
independent of JAK1, once again supporting 
the hypothesis of a cytokine receptor-
independent activation mode.  
To confirm the lack of JAK1 requirement for 
constitutive JAK3L857P signaling in 
hematopoietic cells, endogenous JAK1 
knockdown was performed as described for γc 
(figure 3C). This knockdown decreased the 
proliferation of Ba/F3 cells transformed with 
JAK3V674A, while it did not alter the 
proliferation of cells transformed by JAK3L857P 
or JAK3L857P/Y100A. Taken together, these 
results revealed JAK3L857P as possessing a 
unique characteristic: the capacity to activate 
signaling in the absence of binding to a 
cognate cytokine receptor complex. This 
contrasts with the other tested JAK3 mutants 
as well as all JAK1 and JAK2 activating 
mutants described in the literature (20,21). 
Given that the leucine 857 of JAK3 was 
conserved among all JAK kinases, we sought 
to determine if mutations of the homologous 
residue in JAK1 (L910) and JAK2 (L884) 
could confer a similar receptor-independent 
constitutive signaling capacity. Those 
mutations were introduced together with the 
FERM domain mutations Y107A in JAK1, or 
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Y114A in JAK2 (homologous to Y100A in 
JAK3). As illustrated in figure 4, upon 
transient expression in HEK293 cells, 
JAK1L910P/Y107A and JAK2L884P/Y114A were 
capable of activating STAT5, demonstrating 
that the activating mutations of a leucine 
residue conserved among JAK kinases share 
the capacity of inducing STAT5 activation 
independently of the receptor-FERM domain 
interaction. 
To gain more insight about potential 
mechanisms enabling receptor-independent 
constitutive activation of JAK3L857P, we 
substituted L857 with different residues and 
tested the receptor-independent activity of 
these JAK3 mutants in HEK293 cells, using 
JAK3 cloned in either pMX-IRES-CD4 
(Figure 5A) or pMSCV-GFP (Figure 5B). 
Receptor-independent constitutive STAT5 
activation was observed after replacing the 
leucine with a proline, alanine or glutamine, 
but not with a glutamic acid, probably due to 
this residue’s negative charge, even if the 
mutant was still active in presence of IL-9, 
(data not shown).  
 
Another kinase domain mutant, JAK3L875H, 
exhibits the same receptor-independent 
activating capacity as JAK3L857P- Among the 
JAK3 mutants studied here, L857P was the 
only mutant involving the kinase domain, 
raising the hypothesis that cytokine receptor 
independence could be explained solely by the 
mutation’s location in the kinase domain, 
compared to the pseudokinase mutations that 
would be receptor-dependent. To address this 
question, other activating mutations of the 
kinase domain were investigated. These 
consisted of one JAK3 mutation associated 
with T-cell pro-lymphocytic leukemia 
(Y824D; (24)), three ALL-associated mutants 
(L875H, P906S, E958K; Jan Cools, 
unpublished data), and one mutant described 
in a murine T-cell line (T848A;(16)). As 
illustrated in figure 6A, four out of these five 
new mutants were dependent on the co-
expression of IL-9Rα and γc for their activity 
in HEK293 cells. In contrast, JAK3L875H 
behaved like JAK3L857P, exhibiting a receptor-
independent activating capacity. The close 
proximity of L857P and L875H mutants to the 
α-helix C of the kinase domain is illustrated in 
the predicted protein structure of JAK3 kinase 
domain, represented in figure 6B. By contrast, 
the receptor-dependent mutants map to the 
interface between pseudokinase and kinase 
domains, as previously described (16). 
 
The difference in cytokine-receptor 
requirement correlates to a distinct JAK 
inhibitor specificity- Given that JAK3L857P and 
the other JAK3 mutants presented different 
receptor and JAK1 requirements, we sought to 
determine if they would exhibit the same 
sensitivity to ruxolitinib, a JAK1-2 inhibitor. 
In order to assess this, we treated growth 
factor-independent Ba/F3 cells obtained after 
stable transduction with JAK3V674A, JAK3L857P, 
and JAK3L857P/Y100A, with increasing 
ruxolitinib concentrations and measured their 
proliferation using a tritiated thymidine 
incorporation assay. We employed Ba/F3 cells 
that had been stably transduced with the 
chronic myeloid leukemia-associated BCR-
ABL fusion gene as a negative control, 
choosing this particular oncogene for its lack 
of sensitivity to JAK inhibitors. Figure 7A 
illustrates that Ba/F3 cells transformed with 
JAK3V674A were at least ten fold more 
sensitive to ruxolitinib than those transformed 
with JAK3L857P and JAK3L857P/Y100A. The 
calculated IC50 are shown in Table 1. This 
difference in ruxolitinib sensitivity between 
the V674A and L857P/Y100A JAK3 mutants 
was reproduced in transiently transfected 
HEK293 cells treated with 0.5µM of 
ruxolitinib, STAT5 transcriptional activity 
being used as readout (figure 7B). To 
complement these observations, we monitored 
the phosphorylation status of STAT5, JAK1, 
and JAK3 in growth factor-independent 
JAK3V674A and JAK3L857P/Y100A Ba/F3 cells 
treated with 0.5, 1, and 2µM of ruxolitinib 
(figure 7C). This JAK1-2 inhibitor abrogated 
STAT5 phosphorylation induced by the 
V674A mutant, whereas it had a marginal 
effect on the L857P/Y100A double mutant, 
thus confirming the difference in ruxolitinib 
sensitivity. While able to inhibit STAT5 
phosphorylation by JAK3V674A, ruxolitinib did 
not inhibit JAK1 phosphorylation, probably 
because it is a type I kinase inhibitor, blocking 
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the kinase in an active conformation that can 
still be phosphorylated by JAK3. JAK3 
phosphorylation was only observed in the 
double mutant cells, with no ruxolitinib-
induced inhibition observed, in line with the 
absence of effect seen with STAT5. 
Altogether, these results demonstrate that the 
activity of JAK3V674A can be blocked with a 
JAK1-specific inhibitor, while JAK1-
independent JAK3L857P is much less sensitive 
to ruxolitinib.  
We next tested the effect of a JAK3-specific 
inhibitor (NIBR3049; (17)) on the different 
JAK3 mutants by performing the same 
experiments as for ruxolitinib. As illustrated in 
figure 8A, the Ba/F3 cells transformed with 
JAK3L857P and JAK3L857P/Y100A proved more 
sensitive to NIBR3049 than those transformed 
with JAK3V674A. The calculated IC50 are 
shown in Table 1. Similar results were 
obtained for STAT5 activity in HEK293 cells 
(figure 8B). In Ba/F3 cells, the NIBR3049 
inhibitor completely blocked STAT5 and 
JAK3 phosphorylation in the JAK3L857P/Y100A 
cells, confirming their sensitivity to this 
molecule (figure 8C). By contrast, NIBR3049 
barely affected STAT5 and JAK1 
phophorylation in JAK3V674A cells and even 
increased JAK3 phosphorylation because this 
type I inhibitor blocked JAK3 in the active 
conformation without affecting the kinase 
activity of the JAK1 partner. Altogether, these 
results show that JAK3L857P activity can be 
blocked by a JAK3-specific inhibitor, whereas 
the JAK3V674A is much less sensitive to 
NIBR3049. Finally, when an inhibitor active 
against both JAK1 and JAK3 was used 
(tofacitinib), both receptor-dependent and -
independent mutants exhibited a similar 
sensitivity, as illustrated by a decrease in the 
proliferation of Ba/F3 cells and in STAT5 
activity in HEK293 cells (figure 9). 
 
JAK3 mutants cause distinct leukemia 
phenotypes in a murine hematopoietic stem 
cell transplant model- Degryse et al. reported 
that mice transplanted with bone marrow 
progenitor cells expressing T-ALL-associated 
JAK3 mutants developed a disease resembling 
T-ALL, characterized by an accumulation of 
immature CD8 positive T-cells (13). This 
phenotype can be explained as the result of 
constitutive activation of γc-associated 
receptors, which are essential for T-cell 
lymphoproliferation. Given that JAK3L857P and 
JAK3L857P/Y100A exhibit no cytokine receptor 
restriction in vitro, we wondered if their 
expression in hematopoietic stem cells would 
be leukemogenic and produce the same 
phenotype in vivo. Hematopoietic progenitor 
cells were transduced with retroviral vectors 
expressing JAK3V674A, JAK3L857P, or 
JAK3L857P/Y100A, together with green 
fluorescent protein (GFP), and injected into 
irradiated Balb/c mice. As shown in table 2, 
almost all the mice exhibited increased white 
blood cell (WBC) counts ranging from 20,000 
to 300,000 cells/microliter at sacrifice, within 
50 to 200 days post-transplant. JAK3V674A 
mice displayed an accumulation of CD8 single 
positive cells in the spleen and bone marrow 
(table 2A and figure 10A), as well as in the 
peripheral blood, thymus, lymph nodes (data 
not shown). These mice homogenously 
developed a disease resembling T-ALL, 
similar to the one described by Degryse et al. 
By contrast, JAK3L857P and JAK3L857P/Y100A 
were found to induce at least four different 
types of lympho- or myeloproliferative 
diseases, characterized by an accumulation of 
either CD4/8 double positive T-lymphocytes 
(table 2B and figure 10B), Gr1 positive 
myeloid cells (table 2C and figure 10C), CD8 
single positive T-lymphocytes (table 2D and 
figure 10D), or B220 positive B-lymphocytes 
(table 2E and figure 10E). These results 
indicated that JAK3L857P and JAK3L857P/Y100A 
exhibit an oncogenic potential in vivo, but 
induced a more heterogeneous phenotype 
compared to cytokine receptor-restricted JAK 
mutants. 
 
DISCUSSION 
The originality of our observations resides in 
the demonstration that cancer-associated 
activating mutations of different residues in 
the same JAK kinase induce different 
functional properties, both in vitro and in vivo. 
In vitro, different ALL-associated JAK3 
mutants were associated with distinct 
sensitivity to JAK inhibitors, while the in vivo 
transduction of these mutants in hematopoietic 
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precursors produced distinct leukemia 
phenotypes. This can, for the most part, be 
explained by the unexpected behavior of 
JAK3L857P, which did not require cytokine 
receptor binding in order to be active. These 
findings contrast sharply with what has 
previously been published about other cancer-
associated JAK mutants (20,21), including 
JAK3V674A, which required binding to a 
functional receptor complex in order to be 
active.  
The different phenotypes observed in vivo can 
also be explained by the different cytokine 
receptor requirements of the various mutations 
tested. The transduction of murine 
hematopoietic cells with JAK3V674A led to 
homogenous lymphoblastic leukemias. As the 
oncogenic activity of this mutant is restricted 
to cells expressing γc, downstream constitutive 
signaling mimics the signaling induced by γc-
associated receptors like IL-2R, IL-7R or IL-
9R, which are essential for 
lymphoproliferation. In contrast, transduction 
with JAK3L857P induced various types of 
lymphoid and myeloid leukemias in mice, 
revealing the existence of a broader oncogenic 
potential resulting from the absence of 
cytokine receptor restriction. 
The second key observation reported here is 
that different activating mutations of JAK3 
dictate specific pattern of sensitivity to JAK 
inhibitors. Such different sensitivities to JAK 
inhibitors could be explained by the model 
presented in figure 11. Cytokine receptor 
complexes are formed of two chains, each 
associated with one JAK, namely JAK1 and 
JAK3 for the γc cytokine receptor family 
(figure 11A). JAK3L857P, while still able to 
bind to γc, does not require this binding to be 
active. This explains its JAK1 independent 
activity and accounts for the inefficacy of 
JAK1 inhibitors, such as ruxolitinib (figure 
11B). In contrast, a JAK1 inhibitor blocks the 
activity of classical JAK3 mutants, such as 
JAK3V674A, since these mutants are dependent 
on a functional cytokine receptor complex for 
signaling. A JAK3-specific inhibitor, such as 
NIBR3049, effectively inhibits the activity of 
JAK3L857P (figure 11C). Its relative inefficacy 
against JAK3V657A is in line with the role of 
the kinase activity of JAK3 in the context of 
IL-2 signaling, as reported by Haan et al. (1). 
Indeed, these authors demonstrated that 
although signal transduction by the IL-2R 
complex required JAK3 expression, it was not 
abrogated by a kinase-defective JAK3, 
suggesting that JAK1 kinase activity was 
sufficient for the complex to be active, with 
JAK3 serving as a scaffold protein. One 
hypothesis is therefore that classical mutants, 
such as JAK3V674A, modify the conformation 
of JAK3 as a scaffold in the receptor complex 
in order to enable JAK1 constitutive kinase 
activity.  
Our findings provide further evidence that 
although up to 30% of ALL cases might 
harbor activating mutations of the IL-7R-
JAK1-JAK3 pathway, working with JAK 
inhibitors to treat such hematological 
neoplasms will not be a simple task. The 
selection and dosing of the inhibitor must not 
only be based on the kinase affected, but also 
on the specific mutation observed. We 
previously showed that activating mutations 
affecting Phe958 and Pro960 of JAK1 not 
only promoted autonomous cell proliferation, 
but also conferred resistance to ATP-
competitive inhibitors, suggesting that 
mutations of the same kinase could require 
different JAK inhibitor dosages (25). This also 
proved true for mutations of the JAK2 Tyr931 
residue (25) and, furthermore, applied to the 
homologous mutation of the Tyr904 residue of 
JAK3 (16). Our current study has 
demonstrated that different JAK inhibitors are 
required to block different JAK3 mutants, 
depending on their mechanisms of signal 
transduction activation. While JAK1 (L910P) 
and JAK2 (L884P) mutations that are 
homologous to L857P also induce cytokine 
receptor-independent constitutive signaling, 
their effect on JAK inhibitor sensitivity should 
be less critical, as many JAK2-associated 
receptors are homodimeric and the kinase 
activity of JAK1 appears essential for γc-
associated receptors. 
The mechanisms enabling the receptor-
independent constitutive activation of 
JAK3L857P are still subject to speculation. For 
JAK3, receptor-independent constitutive 
activation is observed after replacing the 
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leucine with different residues (figure 5), 
except for glutamic acid.  JAK3L857Q has been 
described in ALL patients (13), and is also 
receptor-independent. The L910Q mutation of 
JAK1 has already been described as activating 
in a random mutagenesis screening analysis 
(26), and introducing the Y107A mutation 
(homologous to the JAK3 Y100A mutation) in 
the FERM domain of JAK1L910Q has been 
found to not completely abolish STAT5 
constitutive phosphorylation. The diversity of 
these residues suggests that the loss of leucine 
857 is the key factor inducing constitutive 
activation. Interestingly, the leucine 857 of 
JAK3 is not only conserved among all JAK 
kinases, but also in other tyrosine kinases, 
such as c-Src, LCK, c-ABL, EGFR, FGFR, 
and PDGFR. The relevance of this residue for 
kinase activity regulation is illustrated by the 
EGFR exon 19 insertions leading to the L747P 
mutation described in patients with lung 
adenocarcinoma, or by the L747S mutation of 
the EGFR, reported in patients acquiring 
secondary resistance to EGFR inhibitors. It is 
believed to shift the equilibrium towards the 
receptor’s active conformation (27-29). Other 
arguments point towards the importance of the 
JAK αC helix in the regulation of the cytokine 
receptor dependence. As illustrated in 4B, the 
L857 residue is situated in front of the αC 
helix of the N-lobe of the JAK3 kinase domain. 
This alpha helix is conserved among all 
kinases and constitutes a key mediator of 
conformational change between the kinase’s 
active and inactive state (30). Additionally, 
another mutation located within the αC helix 
of JAK3, L875H, is present in patients with 
ALL, exhibiting the same characteristics as 
L857P, namely constitutive activation and 
receptor independence.  
A further puzzling observation is that when 
the Y100A mutation was added to the active 
JAK3L857P mutant, STAT5 activation was seen 
to increase in HEK293 cells. A preliminary 
explanation for this could be that Y100A 
increases L857P-induced constitutive kinase 
activity. Previous studies have, in fact, 
suggested that the FERM domain fulfills a 
regulatory role in kinase activity through 
interaction between the kinase and FERM 
domains (2,31,32) Moreover, electron 
microscopy JAK1 imaging revealed this 
protein as exhibiting a high flexibility, able to 
shuttle from open to closed states (32). In the 
compact conformation, the FERM domain 
comes in close proximity to the kinase domain. 
The Y100A mutation could change these 
interactions and increase the kinase activity 
induced by L857P. Another explanation could 
reside in the subcellular location of the kinase. 
JAK3V674A needs to bind to a cytokine receptor 
in order to be active, with a kinase activity 
located close to the plasma membrane. The 
localization of JAK3L857P/ Y100A is unknown, 
yet cytokine-receptor independent. The 
constitutive kinase activity could therefore 
take place in a location where the activation of 
downstream signaling is more efficient, such 
as the cytoplasm. Further studies will be 
needed to address these issues 
Because of their particular mode of action, the 
cytokine receptor-independent active mutants 
of JAK kinases described here open new 
perspectives, not only for treating patients 
with alterations of the JAK-STAT pathway, 
but also for a better understanding of this 
pathway.
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FOOTNOTES 
The abbreviations used are: ALL, Acute Lymphoblastic Leukemia; AMKL, Acute 
Megakaryoblastic Leukemia; γc, Common Gamma Chain; EpoR, Erythropoietin Receptor; GFP, 
Green Fluorescent Protein; IL, Interleukine; IL-2R, Interleukine 2 receptor; IL-9R, Interleukine 9 
receptor; IL-9Rα, Alpha Chain of the Interleukine 9 Receptor; JAK, Janus Kinase; JMML, 
Juvenile Myelomonocytic Leukemia; KD, Kinase-Dead; LHRE, Lactogenic Hormone Response 
Element MPN, Myeloproliferative neoplasm; SCID, Severe Combined Immunodeficiency 
Syndrome; STAT, Signal Transducer and Activator of Transcription;  WBC, white blood cells 
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FIGURE 1. STAT5 activation by JAK3 activating mutants is receptor-dependent, except for the 
L857P mutant- JAK3- and γc-deficient HEK293 cells were transiently co-transfected with 
JAK3WT, or ALL-associated A572V, V674A, M511I and L857P JAK3 mutants, and γc and/or IL-
9Rα, in addition to the STAT5-responsive luciferase reporter pLHRE-luc (firefly luciferase) and 
the pRLTK plasmid (renilla luciferase) as transfection control. 24 hours post-transfection, cells 
were subjected to a luciferase assay. The relative luciferase activity corresponds to the firefly 
luciferase light emission values divided by the renilla luciferase light emission values. Results are 
mean ± standard deviation of triplicates. Similar results were obtained in 3 independent 
experiments. Kruskal-Wallis test with Dunn Correction was performed to determine p-values 
between the control condition without JAK3 and the WT or mutant forms of JAK3 for each 
condition (with or without IL-9R complex) (*p<0.05, **p<0.01).  
 
FIGURE 2. JAK3 FERM domain integrity is required for the activity of the V674A mutant, but 
not for the L857P mutant- (A) HEK293 cells were transiently co-transfected either with JAK3WT, 
or different JAK3 mutants (Y100A, V674A, L857P), or double mutants (V674A/Y100A, 
L857P/Y100A) together with γc and IL-9Rα or not, in addition to the STAT5-responsive 
luciferase reporter pLHRE-luc (firefly luciferase) and the pRLTK plasmid (renilla luciferase) as 
transfection control. 24 hours post-transfection, cells were subjected to a luciferase assay. The 
relative luciferase activity corresponds to the firefly luciferase light emission values divided by 
the renilla luciferase light emission values. Results are mean ± standard deviation of three 
different experiments, each performed in triplicate. Kruskal-Wallis test with Dunn Correction was 
performed to determine p-values between the control condition without JAK3 and the WT or 
mutant forms of JAK3 for each condition (with or without IL-9R complex) (*p<0.05, 
***p<0.001). K = kinase domain, PK = pseudokinase domain. (B) In parallel of the luciferase 
assay, transfected HEK293 cells were lyzed 24 hours post-transfection and subjected to Western 
Blot analysis using an anti-JAK3 antibody and an anti-β-Actin antibody as loading control. (C) 
Relative proliferation of IL-3 dependent Ba/F3 cells or autonomous Ba/F3 cells obtained after 
transduction with ALL-associated JAK3 mutants (V674A and L857P) and double mutant 
(L857P/Y100A)  after knockdown of endogenous γc compared to the proliferation observed with 
an irrelevant control siRNA. After 72 hours, tritiated thymidine incorporation was measured. 
Results are mean ± standard deviation of three different experiments each performed in triplicate. 
Kruskal-Wallis test with Dunn Correction was performed to determine p-values between the IL-3 
dependent control Ba/F3 cells and the transformed Ba/F3 cells (*p<0.05). 
 
 
FIGURE 3. JAK1 expression s required for the activity of the V674A mutant, but not for the 
L857P mutant- (A) JAK1-deficient U4C cells were transiently co-transfected with JAK3WT or 
JAK3V674A, γc and IL-9Rα with or without JAK1WT or JAK1KD, in addition to the STAT5-
responsive luciferase reporter pLHRE-luc (firefly luciferase) and the pRLTK plasmid (renilla 
luciferase) as transfection control. 24 hours post-transfection, cells were subjected to a luciferase 
assay. The relative luciferase activity corresponds to the firefly luciferase light emission values 
divided by the renilla luciferase light emission values. Results are mean ± standard deviation of 
three different experiments, each performed in triplicate. Kruskal-Wallis test with Dunn 
Correction was performed to determine p-values (*p<0.05) (B) JAK1-deficient U4C cells were 
transiently co-transfected with JAK3WT or JAK3L857P, γc and IL-9Rα with or without JAK1WT or 
JAK1KD, in addition to the STAT5-responsive luciferase reporter pLHRE-luc and the pRLTK 
plasmid as transfection control. 24 hours post-transfection, cells were subjected to a luciferase 
assay. Results are mean ± standard deviation of three different experiments, each performed in 
triplicate. Kruskal-Wallis test with Dunn Correction was performed to determine p-values 
(*p<0.05). (C) Relative proliferation of IL-3 dependent Ba/F3 cells or autonomous Ba/F3 cells 
Receptor-independent activating JAK3 mutants 
15 
 
obtained after transduction with ALL-associated JAK3 mutants (V674A and L857P) and double 
mutant (L857P/Y100A)  after knockdown of endogenous JAK1 compared to the proliferation 
observed with an irrelevant control siRNA. After 72 hours, tritiated thymidine incorporation was 
measured. Results are mean ± standard deviation of three different experiments each performed in 
triplicate. Kruskal-Wallis test with Dunn Correction was performed to determine p-values 
between the IL-3 dependent control Ba/F3 cells and the transformed Ba/F3 cells (**p<0.01). 
 
FIGURE 4. Integrity of the FERM domain is not required for activation of JAK1 and JAK2 
through homologous mutation of JAK3L857P- (A) HEK293 cells were transiently co-transfected 
with ALL-associated JAK1V658F, JAK1L910P (homologous to JAK3 L857P), or JAK1L910P/Y107A, 
with or without IL-9Rα, in addition to the STAT5-responsive luciferase reporter pLHRE-luc 
(firefly luciferase) and the pRLTK plasmid (renilla luciferase) as transfection control. 24 hours 
post-transfection, cells were subjected to a luciferase assay. The relative luciferase activity 
corresponds to the firefly luciferase light emission values divided by the renilla luciferase light 
emission values. Results are mean ± standard deviation of means of three different experiments, 
each performed in triplicate. Kruskal-Wallis test with Dunn Correction was performed to 
determine p-values between the control condition without JAK1 and the mutant forms of JAK1 
for each condition (with or without IL-9Rα) (*p<0.05, **p<0.01, ***p<0.001). (B) HEK293 cells 
were transiently co-transfected with MPN-associated JAK2V617F, JAK2L884P (homologous to JAK3 
L857P), or JAK2L884P/Y114A, in addition to the STAT5-responsive luciferase reporter pLHRE-luc 
and the pRLTK plasmid as transfection control. 24 hours post-transfection, cells were subjected 
to a luciferase assay. Results are mean ± standard deviation of means of triplicates of three 
different experiments. Kruskal-Wallis test with Dunn Correction was performed to determine p-
values between the control condition without JAK2 and the mutant forms of JAK2 (*p<0.05, 
***<0.001).  
 
FIGURE 5. Substitution of L857 of JAK3 with different residues can confer receptor-
independent constitutive activity- HEK293 cells were transiently transfected either with wild-type 
JAK3, or different JAK3 mutants: (A) JAK3WT, JAK3V674A, JAK3L857P, JAK3L857A, JAK3L857E in 
pMX-IRES-CD4 and (B) JAK3WT, JAK3V674A, JAK3L857P, JAK3L857Q in pMSCV-GFP. The 
STAT5-responsive luciferase reporter pLHRE-luc (firefly luciferase) and the pRLTK plasmid 
(renilla luciferase) were co-transfected. 24 hours post-transfection, cells were subjected to a 
luciferase assay. The relative luciferase activity corresponds to the firefly luciferase light 
emission values divided by the renilla luciferase light emission values. Results are mean ± 
standard deviation of means of three different experiments, each performed in triplicate. Kruskal-
Wallis test with Dunn Correction was performed to determine p-values between the control 
condition without JAK3 and the WT or mutant forms of JAK3 for each condition (*p<0.05, 
**p<0.01, ***p<0.001). 
 
 
FIGURE 6. The majority of kinase domain mutants are receptor-dependent, except JAK3L857P 
and JAK3L875H- (A) HEK293 cells were transiently co-transfected either with JAK3WT, or 
different JAK3 mutants (V674A, L857P, Y824A, T848A, L875H, P906S, E958K), in addition to 
the STAT5-responsive luciferase reporter pLHRE-luc (firefly luciferase) and the pRLTK plasmid 
(renilla luciferase) as transfection control. 24 hours post-transfection, cells were subjected to a 
luciferase assay. The relative luciferase activity corresponds to the firefly luciferase light 
emission values divided by the renilla luciferase light emission values. Results are mean ± 
standard deviation of means of three different experiments, each performed in triplicate. Kruskal-
Wallis test with Dunn Correction was performed to determine p-values between the control 
condition without JAK3 and the WT or mutant forms of JAK3 for each condition (*p<0.05, 
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**p<0.01, ***p<0.001). (B) Localization of ALL-associated JAK3 mutants of the kinase domain. 
The figure represents the kinase and pseudo-kinase domains of JAK3 based on the recent TYK2 
JH1/JH2 crytsal structure (33). The kinase domain is shown in indigo, with the αC helix in yellow 
and the activation loop in orange. The adjacent pseudokinase domain is shown in green. Mutated 
residues close to the pseudokinase domain are indicated with pink balls and mutated residues 
close to the αC helix are indicated with light-blue balls. 
 
FIGURE 7. Cells expressing JAK3V674A mutant are more sensitive to Ruxolitinib than cells 
expressing JAK3L857P or JAK3L857P/Y100A- (A) Autonomous Ba/F3 cells stably transduced with 
ALL-associated JAK3 mutants (V674A and L857P) and double mutant (L857P/Y100A) or BCR-
ABL as a control, were treated with increasing concentrations of JAK1/JAK2 inhibitor 
Ruxolitinib (0-3µM). After 72 hours, tritiated thymidine incorporation was measured. Results are 
mean ± standard deviation of three different experiments each performed in triplicate, represented 
in % of the proliferation of the respective untreated cells. (B) HEK293 cells were transiently co-
transfected either with JAK3V674A or JAK3L857P/Y100A, with a receptor complex (Rec = γc, IL-9Rα 
and JAK1WT), in addition to the STAT5-responsive luciferase reporter pLHRE-luc (firefly 
luciferase) and the pRLTK plasmid (renilla luciferase) as transfection control. Cells were treated 
with Ruxolitinib (1µM). 24 hours post-transfection, cells were subjected to a luciferase assay. 
The relative luciferase activity corresponds to the firefly luciferase light emission values divided 
by the renilla luciferase light emission values. Results are mean ± standard deviation of three 
different experiments, each performed in triplicate. Kruskal-Wallis test with Dunn Correction was 
performed to determine p-values (*p<0.05). (C) 106 autonomous Ba/F3 cells stably transduced 
with ALL-associated JAK3 mutant V674A or double-mutant L857P/Y100A were treated with 
increasing concentration of Ruxolitinib (0-2µM). Two hours after treatment, cells were lyzed and 
subjected to Western Blot analysis. Phosphorylation of STAT5, JAK3 and JAK1 was detected 
using specific anti-pY694 STAT5, anti-pY980/81 JAK3, and anti-pY1034/35 JAK1 antibodies. 
Membranes were re-probed with anti-STAT5, anti-JAK3, anti-JAK1 and anti-β-Actin antibodies 
as loading controls.  
 
FIGURE 8. Cells expressing JAK3 L857P or L857P/Y100A mutants are more sensitive to 
NIBR3049 than cells expressing JAK3 V674A- (A) Autonomous Ba/F3 cells stably transduced 
with ALL-associated JAK3 mutants (V674A and L857P) and double mutant (L857P/Y100A) or 
BCR-ABL as a control, were with increasing concentrations of JAK3 inhibitor NIBR3049 (0-
2µM). After 72 hours, tritiated thymidine incorporation was measured. Results are mean ± 
standard deviation of three different experiments each performed in triplicate, represented in % of 
the proliferation of the respective untreated cells. (B) HEK293 cells were transiently co-
transfected either with JAK3V674A or JAK3L857P/Y100A, with a receptor complex (Rec = γc, IL-9Rα 
and JAK1WT), in addition to the STAT5-responsive luciferase reporter pLHRE-luc (firefly 
luciferase) and the pRLTK plasmid (renilla luciferase) as transfection control. Cells were treated 
with NIBR3049 (0.5µM). 24 hours post-transfection, cells were subjected to a luciferase assay. 
The relative luciferase activity corresponds to the firefly luciferase light emission values divided 
by the renilla luciferase light emission values. Results are mean ± standard deviation of three 
different experiments, each performed in triplicate. Kruskal-Wallis test with Dunn Correction was 
performed to determine p-values (*p<0.05). (C) 106 autonomous Ba/F3 cells stably transduced 
with ALL-associated JAK3 mutant V674A or double-mutant L857P/Y100A were treated with 
increasing concentration of NIBR3049 (0-4µM). Two hours after treatment, cells were lyzed and 
subjected to Western Blot analysis. Phosphorylation of STAT5, JAK3 and JAK1 was detected 
using specific anti-pY694 STAT5, anti-pY980/81 JAK3, and anti-pY1034/35 JAK1 antibodies. 
Membranes were re-probed with anti-STAT5, anti-JAK3, anti-JAK1 and anti-β-Actin antibodies 
as loading controls.  
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FIGURE 9. Cells expressing JAK3 V674A, L857P and L857P/Y100A mutants are sensitive to 
Tofacitinib- (A) Autonomous Ba/F3 cells stably transduced with ALL-associated JAK3 mutants 
(V674A and L857P) and double mutant (L857P/Y100A) or BCR-ABL as a control, were treated 
with increasing concentrations of JAK1/JAK3 inhibitor Tofacitinib (0-3µM). After 72 hours, 
tritiated thymidine incorporation was measured. Results are mean ± standard deviation of three 
different experiments each performed in triplicate, represented in % of the proliferation of the 
respective untreated cells. (B) HEK293 cells were transiently co-transfected either with 
JAK3V674A or JAK3L857P/Y100A, with a receptor complex (Rec= γc, IL-9Rα and JAK1WT), in 
addition to the STAT5-responsive luciferase reporter pLHRE-luc (firefly luciferase) and the 
pRLTK plasmid (renilla lucifearse) as transfection control. Cells were treated with Tofacitinib 
(0.5µM). 24 hours post-transfection, cells were subjected to a luciferase assay. The relative 
luciferase activity corresponds to the firefly luciferase light emission values divided by the renilla 
luciferase light emission values. Results are mean ± standard deviation of three different 
experiments, each performed in triplicate. Kruskal-Wallis test with Dunn Correction was 
performed to determine p-values (*p<0.05).  
 
 
FIGURE 10. Expression of JAK3 mutants in bone marrow cells of Balb/c mice leads to distinct 
leukemia phenotypes- Spleen and bone marrow cells of diseased animals were analysed by flow 
cytometry with anti-CD4, anti-CD8, anti-Gr1 and anti-B220 antibodies. Cells were gated for GFP 
expression. FACS analysis representative of a CD8+ T-lymphoproliferation in a JAK3V674A 
mouse (A), a CD4/8+ T-lymphoproliferation in a JAK3L857P mouse (B), a Gr1+ 
myeloproliferation in a JAK3L857P/Y100A mouse (C), a CD8+ T-lymphoproliferation in a 
JAK3L857P/Y100A mouse (D) and a B220+ B-lymphoproliferation in a JAK3L857P mouse  (E) are 
shown, either as dot plots (spleen) or as stacked column charts representing the percentage of 
cells positive for the different markers (bone marrow). 
 
FIGURE 11. Schematic representation of JAK3 mutants’ activity under JAK inhibitor treatment 
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Table 1 
 
TABLE 1. Calculated IC50 values (µM) of NIBR3049, Ruxolitinib and Tofacitinib in 
autonomous Ba/F3 cells- The table shows the calculated IC50 values (in µM) of autonomous 
Ba/F3 cells stably transduced with ALL-associated JAK3 mutants (V674A and L857P) or double 
mutant (L857P/Y100A), treated with Ruxolitinib, NIBR3049 and Tofacitinib. The IC50 mean 
values and standard error of the mean (SEM) values were calculated on means of triplicates 
cultures from three different experiments.  
 
 
 
 
JAK1/2 inhibitor JAK3 inhibitor JAK1/3 inhibitor 
Ruxolitinib NIBR3049 Tofacitinib IC50 (μM) 
Mean SEM Mean SEM Mean SEM 
Ba/F3 JAK3V674A 0.1 0.03 3.42 0.22 0.17 0.05 
Ba/F3 JAK3L857P 1.26 0.2 1.15 0.21 0.32 0.03 
Ba/F3 JAK3L857P/Y100A 2.33 0.21 1.31 0.24 0.44 0.05 
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Table 2 
 
TABLE 2. Expression of JAK3 mutants in bone marrow cells of Balb/c mice leads to distinct 
leukemia phenotypes- The table shows the days post-transplant at sacrifice, the white blood cells 
(WBC) count at sacrifice, and the diagnosis of Balb/c mice receiving a bone marrow 
transplantation of lineage negative cells expressing JAK3V674A, JAK3L857P or JAK3L857P/Y100A. Five 
different diagnosis were observed: CD8+ T-lymphoproliferation in JAK3V674A mice (A), CD4/8+ 
T-lymphoproliferation in JAK3L857P and JAK3L857P/Y100A mice (B),  Gr1+ myeloproliferation in 
JAK3L857P and JAK3L857P/Y100A mice (C), another type of CD8+ T-lymphoproliferation in 
JAK3L857P and JAK3L857P/Y100A mice (D) and  B220+ B-lymphoproliferation in a JAK3L857P mice  
(E) 
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